Clinical Trial Detail

NCT ID NCT02104427
Title PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements no
Sponsors TaiGen Biotechnology Co., Ltd.
Indications

multiple myeloma

non-Hodgkin lymphoma

Hodgkin's lymphoma

Therapies

TG-0054

Filgrastim

Age Groups: adult

No variant requirements are available.